The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...
Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025 Series B Financing Funds AUTX-703 Development through Phase 1 Clinical ...
Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...